PTGX

Protagonist Therapeutics, Inc. (PTGX) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended March 31, 2026. Protagonist Therapeutics is a biopharmaceutical company focused on peptide therapeutics in inflammation/immunology, hematology, and metabolic diseases. Key milestones in this period include the FDA approval of ICOTYDE (icotrokinra) for plaque psoriasis in March 2026 and the submission of a New Drug Application (NDA) for rusfertide for polycythemia vera (PV) in December 2025, which received Priority Review.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Revenue nearly doubled (99% increase) primarily due to a $50.0 million milestone payment from Johnson & Johnson (JNJ) upon FDA approval of ICOTYDE. Takeda collaboration revenue decreased to $6.4 million from $28.3 million as the prior period included a significant milestone recognition.
• Profitability Turnaround: The company reported a net income of $3.8 million compared to a net loss of $11.7 million in Q1 2025. This was driven by the milestone revenue and a $1.5 million income tax benefit.
• Expense Growth: Research and Development (R&D) expenses increased 30% to $46.7 million, driven by the initiation of Phase 1 trials for PN-881 and increased pre-clinical discovery costs, partially offset by lower rusfertide expenses following the completion of its Phase 3 trial.
• Cash Flow Volatility: Operating cash flow swung from positive $125.4 million in Q1 2025 to negative $48.9 million in Q1 2026. The prior year included a $165 million cash receipt from JNJ, whereas the current quarter's $50 million milestone was recorded as a receivable (non-cash in operating activities).

Outlook, Management Commentary, and Risks

• Subsequent Event - Takeda Opt-Out: On April 28, 2026, the company exercised its right to opt out of the U.S. profit/loss sharing arrangement with Takeda for rusfertide. This triggered an immediate $200.0 million payment, with an additional $200.0 million opt-out fee and a $75.0 million milestone payable upon FDA approval. Future royalties are now tiered between 14% and 29% on worldwide net sales.
• Liquidity: Management states that existing cash and marketable securities ($620.3 million) are sufficient to fund operations for at least the next 12 months.
• Pipeline Progress:
  • ICOTYDE: Approved in the U.S.; EMA application submitted in Sept 2025. Phase 3 ongoing for psoriatic arthritis, ulcerative colitis, and Crohn's disease.
  • Rusfertide: NDA under Priority Review with a target FDA action date in Q3 2026. Takeda expects a launch in H2 2026 if approved.
  • Obesity & Other: PN-477 (triple agonist) and PN-458 (dual agonist) nominated as development candidates. PN-881 (IL-17 antagonist) Phase 1 ongoing.
• Risks: Reliance on collaboration partners for commercialization; uncertainty regarding future regulatory approvals; potential need for additional capital if development timelines extend or costs increase.

Key Facts for Investor Verification

• Receivable Status: Verify the collection status of the $53.7 million receivable from JNJ recorded on the balance sheet as of March 31, 2026.
• Takeda Opt-Out Payment: Confirm the receipt of the $200 million opt-out payment triggered in late April 2026 and its impact on Q2 2026 liquidity.
• Rusfertide FDA Decision: Monitor the FDA action date in Q3 2026, which is critical for the $75 million milestone and future royalty streams.
• ICOTYDE Commercialization: Track early sales data and royalty accruals from JNJ following the March 2026 U.S. launch.
• Capital Runway: Assess if the $620 million cash balance remains sufficient given the increased R&D spend on new obesity and IL-17 programs.